TELA Bio, Inc. (NASDAQ:TELA – Get Rating) insider Ew Healthcare Partners Fund 2, purchased 5,000 shares of the stock in a transaction that occurred on Wednesday, May 25th. The shares were purchased at an average price of $6.87 per share, for a total transaction of $34,350.00. Following the completion of the purchase, the insider now directly owns 3,445,709 shares of the company’s stock, valued at $23,672,020.83. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Ew Healthcare Partners Fund 2, also recently made the following trade(s):

• On Friday, May 27th, Ew Healthcare Partners Fund 2, acquired 5,000 shares of TELA Bio stock. The stock was bought at an average price of $7.43 per share, for a total transaction of $37,150.00.
• On Monday, May 23rd, Ew Healthcare Partners Fund 2, purchased 5,000 shares of TELA Bio stock. The shares were acquired at an average cost of $8.53 per share, with a total value of $42,650.00.
• On Friday, May 20th, Ew Healthcare Partners Fund 2, purchased 5,000 shares of TELA Bio stock. The shares were acquired at an average cost of $8.79 per share, with a total value of $43,950.00.
• On Wednesday, May 18th, Ew Healthcare Partners Fund 2, purchased 5,000 shares of TELA Bio stock. The shares were acquired at an average cost of $8.96 per share, with a total value of $44,800.00.
• On Monday, May 16th, Ew Healthcare Partners Fund 2, purchased 5,000 shares of TELA Bio stock. The shares were acquired at an average cost of $8.61 per share, with a total value of $43,050.00.
• On Friday, May 13th, Ew Healthcare Partners Fund 2, purchased 5,000 shares of TELA Bio stock. The shares were acquired at an average cost of $8.48 per share, with a total value of $42,400.00.
• On Wednesday, May 11th, Ew Healthcare Partners Fund 2, acquired 5,000 shares of TELA Bio stock. The stock was purchased at an average price of $8.82 per share, for a total transaction of $44,100.00.
• On Monday, May 9th, Ew Healthcare Partners Fund 2, acquired 5,000 shares of TELA Bio stock. The stock was purchased at an average price of $9.38 per share, for a total transaction of $46,900.00.
• On Friday, May 6th, Ew Healthcare Partners Fund 2, acquired 5,000 shares of TELA Bio stock. The stock was purchased at an average price of $9.55 per share, for a total transaction of $47,750.00.
• On Wednesday, May 4th, Ew Healthcare Partners Fund 2, acquired 5,000 shares of TELA Bio stock. The stock was purchased at an average price of $9.53 per share, for a total transaction of $47,650.00.

Shares of NASDAQ:TELA traded up $0.36 during midday trading on Friday, hitting $7.36. The company had a trading volume of 48,698 shares, compared to its average volume of 34,878. TELA Bio, Inc. has a 12 month low of $6.32 and a 12 month high of $16.53. The company has a current ratio of 4.10, a quick ratio of 3.26 and a debt-to-equity ratio of 3.15. The stock has a market cap of $107.15 million, a price-to-earnings ratio of -2.97 and a beta of 1.57. The firm has a fifty day simple moving average of $9.82 and a 200 day simple moving average of $11.44.

TELA Bio (NASDAQ:TELA – Get Rating) last posted its quarterly earnings results on Tuesday, May 10th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by ($0.25). TELA Bio had a negative return on equity of 155.13% and a negative net margin of 113.15%. During the same period in the prior year, the business earned ($0.56) earnings per share. Equities analysts forecast that TELA Bio, Inc. will post -2.47 EPS for the current fiscal year.

A number of brokerages have commented on TELA. Zacks Investment Research upgraded TELA Bio from a “sell” rating to a “hold” rating in a research report on Tuesday. JMP Securities reiterated a “buy” rating and issued a $22.00 price objective on shares of TELA Bio in a research report on Tuesday, March 22nd.

Several large investors have recently bought and sold shares of TELA. Geode Capital Management LLC lifted its holdings in TELA Bio by 1.3% during the third quarter. Geode Capital Management LLC now owns 64,923 shares of the company’s stock worth $886,000 after acquiring an additional 824 shares in the last quarter. BlackRock Inc. lifted its holdings in TELA Bio by 4.1% during the fourth quarter. BlackRock Inc. now owns 22,392 shares of the company’s stock worth $287,000 after acquiring an additional 886 shares in the last quarter. Pentwater Capital Management LP lifted its holdings in TELA Bio by 0.3% during the fourth quarter. Pentwater Capital Management LP now owns 312,238 shares of the company’s stock worth $3,997,000 after acquiring an additional 1,022 shares in the last quarter. Bank of America Corp DE lifted its holdings in TELA Bio by 16.6% during the second quarter. Bank of America Corp DE now owns 7,682 shares of the company’s stock worth $124,000 after acquiring an additional 1,093 shares in the last quarter. Finally, State Street Corp lifted its holdings in TELA Bio by 9.1% during the first quarter. State Street Corp now owns 26,065 shares of the company’s stock worth $303,000 after acquiring an additional 2,167 shares in the last quarter.

About TELA Bio (Get Rating)

TELA Bio, Inc, a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs.

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Should you invest $1,000 in TELA Bio right now?

Before you consider TELA Bio, you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and TELA Bio wasn’t on the list.

While TELA Bio currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here